BEIJING., Aug. 13, 2020 – Keya Medical Technology Co., Ltd. (Keya Medical), a leader in coronary AI technology development, announced today that it has raised over $20 million in Series B+ funding. The round was led by GGV Capital, Kunlun Worldwide, Guofang Investment, and Yahui Precise Medical Care Fund. The proceeds of the investment will be used for the global commercial development of Keya Medical’s products, providing an important driving force for subsequent product development and market expansion.
While the COVID-19 pandemic has introduced major challenges for some companies, Keya Medical’s growth is accelerating. In just six months, Keya Medical has completed two rounds of strategic financing. Keya Medical has adhered to the product development principle of developing solutions that are based on “real clinical needs,” using funds to bring products to market that empower both clinicians and patients.
Keya Medical will continue to accelerate progress in medical imaging AI. Keya Medical welcomes collaboration partners in the United States and abroad to help support progress worldwide.
About Keya Medical
Keya Medical is focused on empowering healthcare with AI-driven quality and productivity innovations. In Jan. 2020, Keya Medical became the first company in China to receive NMPA approval for Class III software medical device, DEEPVESSEL FFR. DEEPVESSEL FFR is a non-invasive CT-FFR product that uses deep learning technology to perform a physiological functional assessment of the coronary arteries in minutes from coronary computed tomography angiography scans.